The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Validating the prognostic relevance of initial change in tumor size using a series of therapeutic regimens for patients with metastatic colorectal cancer (mCRC).
Ulrich Robert Mansmann
Research Funding - Merck KGaA
Ruediger P. Laubender
Research Funding - Merck KGaA
Other Remuneration - Merck KGaA
Clemens Albrecht Giessen
Other Remuneration - Roche
Ute Sartorius
Employment or Leadership Position - Merck KGaA
Volker Heinemann
Consultant or Advisory Role - Merck KGaA; Roche; Sanofi
Honoraria - Merck KGaA; Roche; Sanofi
Expert Testimony - Merck KGaA; Roche
Other Remuneration - Merck KGaA; Roche